Yoga therapy on elderly patients with fear of fall: an open-label randomised controlled trial (YOFEAR trial)

被引:0
|
作者
Kashyap, Kritartha [1 ]
Dhar, Minakshi [1 ,2 ]
Bisht, Khushboo [3 ]
Bahurupi, Yogesh [4 ]
Pathania, Monika [1 ]
机构
[1] All India Inst Med Sci, Geriatr Med, Rishikesh, Uttarakhand, India
[2] All India Inst Med Sci, Internal Med, Rishikesh, Uttarakhand, India
[3] All India Inst Med Sci, Clin Pharmacol, Rishikesh, Uttarakhand, India
[4] All India Inst Med Sci, Community & Family Med, Rishikesh, Uttarakhand, India
来源
BMJ OPEN | 2023年 / 13卷 / 12期
关键词
GERIATRIC MEDICINE; Health & safety; Quality in health care; Aging; REHABILITATION MEDICINE; OLDER-PEOPLE; BALANCE; GAIT; COMMUNITY; EFFICACY; ADULTS; VALIDATION; EXERCISES;
D O I
10.1136/bmjopen-2022-070540
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Fear of fall is experienced by the elderly irrespective of the presence or absence of history of fall. Falls contribute to injuries that culminate in hospitalisation that incur unwarranted medical expenses. Yoga is unique to Indian cultural practices, with a potential to enhance proprioception. It increases self-body awareness, ultimately improving the balancing capacity of older adults. Thus, the objective of this study is to compare the effect of yoga therapy in the study and control groups at 12 weeks from the baseline.Methods and analysis This study is designed as an open-label, randomised controlled trial (1:1) with a sample size of 62 elderly patients more than or equal to 60 years of age. Participation of either sex, male or female with a fear of fall will be considered. Two randomised groups of 31 participants each will receive standard therapy for their primary diseases as per the local, national or international guidelines. However, participants in the intervention arm will receive additional structured yoga therapy sessions. The primary objective of this study is to assess and compare the change in fear of fall score of participants in each group using Falls Efficacy Scale (FES) and Berg Balance Scale (BBS) at 12 weeks versus baseline. The secondary endpoint will assess the change in the quality of life of participants at 3 months compared with the baseline. Data will be gathered, entered into Microsoft Excel and further analysed by R software (V.4.3.0). Changes in FES-Intervention and BBS of two groups will be compared either by Student's t-test for parametric data or Mann-Whitney U test for non-parametric data. Statistical significance will be considered if p<0.05 at 95% confidence level.Methods and analysis This study is designed as an open-label, randomised controlled trial (1:1) with a sample size of 62 elderly patients more than or equal to 60 years of age. Participation of either sex, male or female with a fear of fall will be considered. Two randomised groups of 31 participants each will receive standard therapy for their primary diseases as per the local, national or international guidelines. However, participants in the intervention arm will receive additional structured yoga therapy sessions. The primary objective of this study is to assess and compare the change in fear of fall score of participants in each group using Falls Efficacy Scale (FES) and Berg Balance Scale (BBS) at 12 weeks versus baseline. The secondary endpoint will assess the change in the quality of life of participants at 3 months compared with the baseline.Data will be gathered, entered into Microsoft Excel and further analysed by R software (V.4.3.0). Changes in FES-Intervention and BBS of two groups will be compared either by Student's t-test for parametric data or Mann-Whitney U test for non-parametric data. Statistical significance will be considered if p<0.05 at 95% confidence level.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Group schema therapy combined with psychomotor therapy for older adults with a personality disorder: an open-label, multicentre, randomised controlled trial
    Veenstra-Spruit, Martine S.
    Bouman, Renske
    Dijk, Silvia D. M. van
    Asselt, Antoinette D. I. van
    Alphen, Sebastiaan P. J. van
    Veenstra, Dorothee H.
    de Ruiter, Marije
    Troost, Saskia E.
    Lammers, Monique W.
    Vulker, Frank
    Smeets-Janssen, Maureen M. J.
    Brink, Rob H. S. van den
    Voshaar, Richard C. Oude
    LANCET HEALTHY LONGEVITY, 2024, 5 (04): : e245 - e254
  • [32] Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Horby, P. W.
    Roddick, A.
    Spata, E.
    Staplin, N.
    Emberson, J.
    Pessoa-Amorim, G.
    Brightling, C.
    Prudon, B.
    Chadwick, D.
    Ustianowski, A.
    Ashish, A.
    Todd, S.
    Yates, B.
    Buttery, R.
    Scott, S.
    Maseda, D.
    Baillie, J. K.
    Buch, M.
    Chappell, L.
    Day, J.
    Faust, S. N.
    Jaki, T.
    Jeffery, K.
    Juszczak, E.
    Lim, W. S.
    Montgomery, A.
    Mumford, A.
    Rowan, K.
    Thwaites, G.
    Mafham, M.
    Haynes, R.
    Landray, M. J.
    Horby, P. W.
    Landray, M. J.
    Baillie, J. K.
    Buch, M.
    Chappell, L.
    Day, J.
    Faust, S. N.
    Haynes, R.
    Jaki, T.
    Jeffery, K.
    Juszczak, E.
    Lim, W. S.
    Mafham, M.
    Montgomery, A.
    Mumford, A.
    Rowan, K.
    Thwaites, G.
    Sandercock, P.
    LANCET, 2021, 397 (10274): : 605 - 612
  • [33] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Horby, Peter W.
    Pessoa-Amorim, Guilherme
    Staplin, Natalie
    Emberson, Jonathan R.
    Campbell, Mark
    Spata, Enti
    Peto, Leon
    Brunskill, Nigel J.
    Tiberi, Simon
    Chew, Victor
    Brown, Thomas
    Tahir, Hasan
    Ebert, Beate
    Chadwick, David
    Whitehouse, Tony
    Sarkar, Rahuldeb
    Graham, Clive
    Baillie, J. Kenneth
    Basnyat, Buddha
    Buch, Maya H.
    Chappell, Lucy C.
    Day, Jeremy
    Faust, Saul N.
    Hamers, Raph L.
    Jaki, Thomas
    Juszczak, Edmund
    Jeffery, Katie
    Lim, Wei Shen
    Montgomery, Alan
    Mumford, Andrew
    Rowan, Kathryn
    Thwaites, Guy
    Mafham, Marion
    Haynes, Richard
    Landray, Martin J.
    LANCET, 2022, 399 (10320): : 143 - 151
  • [34] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Only, Group Author
    LANCET RESPIRATORY MEDICINE, 2021, 9 (12): : 1419 - 1426
  • [35] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Horby, Peter W.
    Landray, Martin J.
    LANCET, 2021, 397 (10285): : 1637 - 1645
  • [36] Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Horby, Peter W.
    Staplin, Natalie
    Peto, Leon
    Emberson, Jonathan R.
    Campbell, Mark
    Pessoa-Amorim, Guilherme
    Basnyat, Buddha
    Thwaites, Louise
    van Doorn, Rogier
    Hamers, Raph L.
    Nel, Jeremy
    Amuasi, John
    Rawal, Manisha
    Ghosh, Dipansu
    Douse, Jonathan
    Hamilton, Fergus
    Kerry, Anthony
    Thu-Ta, Pinky
    Widdrington, John
    Green, Christopher A.
    Desai, Purav
    Stewart, Richard
    Phong, Nguyen Thanh
    Baillie, J. Kenneth
    Buch, Maya
    Faust, Saul N.
    Jaki, Thomas
    Juszczak, Edmund
    Jeffery, Katie
    Knight, Marian
    Lim, Wei Shen
    Montgomery, Alan
    Mukherjee, Aparna
    Mumford, Andrew
    Rowan, Kathryn
    Thwaites, Guy
    Mafham, Marion
    Haynes, Richard
    Landray, Martin J.
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (12): : 905 - 914
  • [37] Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
    Eikelboom, John W.
    Jolly, Sanjit S.
    Belley-Cote, Emilie P.
    Whitlock, Richard P.
    Rangarajan, Sumathy
    Xu, Lizhen
    Heenan, Laura
    Bangdiwala, Shrikant, I
    Tarhuni, Wadea M.
    Hassany, Mohamed
    Kontsevaya, Anna
    Harper, William
    Sharma, Sanjib Kumar
    Lopez-Jaramillo, Patricio
    Dans, Antonio L.
    Palileo-Villanueva, Lia M.
    Avezum, Alvaro
    Pais, Prem
    Xavier, Denis
    Felix, Camilo
    Yusufali, Afzalhussein
    Lopes, Renato D.
    Berwanger, Otavio
    Ali, Zeeshan
    Wasserman, Sean
    Anand, Sonia S.
    Bosch, Jackie
    Choudhri, Shurjeel
    Farkouh, Michael E.
    Loeb, Mark
    Yusuf, Salim
    LANCET RESPIRATORY MEDICINE, 2022, 10 (12): : 1160 - 1168
  • [38] Inased (inhaled sedation in ICU) trial protocol: a multicentre randomised open-label trial
    Bailly, Pierre
    Egreteau, Pierre-Yves
    Ehrmann, Stephan
    Thille, Arnaud W.
    Guitton, Christophe
    Grillet, Guillaume
    Reizine, Florian
    Huet, Olivier
    Jaber, S.
    Nowak, Emmanuel
    L'her, Erwan
    BMJ OPEN, 2021, 11 (02):
  • [39] Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
    Birtle, Alison
    Johnson, Mark
    Chester, John
    Jones, Robert
    Dolling, David
    Bryan, Richard T.
    Harris, Christopher
    Winterbottom, Andrew
    Blacker, Anthony
    Catto, James W. F.
    Chakraborti, Prabir
    Donovan, Jenny L.
    Elliott, Paul Anthony
    French, Ann
    Jagdev, Satinder
    Jenkins, Benjamin
    Keeley, Francis Xavier, Jr.
    Kockelbergh, Roger
    Powles, Thomas
    Wagstaff, John
    Wilson, Caroline
    Todd, Rachel
    Lewis, Rebecca
    Hall, Emma
    LANCET, 2020, 395 (10232): : 1268 - 1277
  • [40] Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial
    Goya, Maria
    Pratcorona, Laia
    Merced, Carme
    Rodo, Carlota
    Valle, Leonor
    Romero, Azahar
    Juan, Miquel
    Rodriguez, Alberto
    Munoz, Begona
    Santacruz, Belen
    Bello-Munoz, Juan Carlos
    Llurba, Elisa
    Higueras, Teresa
    Cabero, Luis
    Carreras, Elena
    LANCET, 2012, 379 (9828): : 1800 - 1806